MedTrace Logo

Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery

NCT00798447 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-06-09

No results posted yet for this study

Summary

Evaluation of the impact of peri- and post-operative parenteral nutrition enriched with n-3 PUFA on post-operative inflammatory processes.

Conditions

  • GI Cancer

Interventions

DRUG

MLF 541

22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour

DRUG

Lipofundin MCT

22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour

Sponsors & Collaborators

  • B.Braun Taiwan Co., Ltd.

    collaborator INDUSTRY

  • B. Braun Melsungen AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00798447 on ClinicalTrials.gov